ATAI LLY(confirmed) lilly to acquire ataibeckley to advance Therapies for treatment-resistant depression and other mental health conditions
ATAI LLY(confirmed) lilly to acquire ataibeckley to advance Therapies for treatment-resistant depression and other mental health conditions Eli Lilly - to pay $6.75 per share cash plus up to $2.5 per share in cvr - Deal valued at $2.8B upfront with up to $1B in cvr - Deal expected to close in Q3 subject to approvals
Story updates
10:46:30 AM UTC
SquawkNews
Eli Lilly To Acquire Ataibeckley To Advance Therapies For Treatment-Resistant Depression And Other Mental Health Conditions
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.